Physician profile
Don Chomsky
NPI 1598719536
$36,527.37
in general payments reported to CMS, 2019-2025
22 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $12K · 2021: $5,189 · 2022: $1,568 · 2023: $1,372 · 2024: $2,015 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,938.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,528.36 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals Lp | $13,604.59 | 2020-2025 | Farxiga, Brilinta |
| Abiomed | $654.24 | 2019-2022 | |
| Boston Scientific Corporation | $332.03 | 2019-2023 | Watchman Access System |
| Cvrx, INC. | $297.28 | 2024-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $165.50 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $133.82 | 2019 | |
| Heartflow, INC. | $123.79 | 2024 | |
| Livanova USA, INC. | $114.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $67.32 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $65.08 | 2022-2024 | Verquvo, Winrevair |
| Amgen INC. | $60.32 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.57 | 2024 | Jardiance |
| Ancora Heart, INC. | $46.65 | 2022-2023 | Accucinch |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.05 | 2021 | |
| Medtronic, INC. | $33.79 | 2021 | |
| Pfizer INC. | $24.05 | 2024 | |
| Amarin Pharma, INC. | $21.28 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.46 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $17.66 | 2024 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Chomsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.